Ditemukan 30614 dokumen yang sesuai dengan query :: Simpan CSV
Penyakit HIV/AIDS merupakan masalah kesehatan di Indonesia. Masalah yang berkembang adalah karena angka morbiditas dan mortalitas yang masih tinggi, disebabkan antara lain karena keterlambatan mendapatkan pengobatan Anti Retroviral (ARV). Di Indonesia pengobatan ARV umumnya dimulai bila jumlah sel CD4 < 200 sel/mm 3 atau bila stadium klinis 3 atau 4. Informasi tentang pengaruh jumlah sel CD4 sebelum pengobatan ARV terhadap ketahanan hidup satu tahun pasien HIV/AIDS berdasarkan kelompok kategori 3 , 50- 3 dan > 200 sel/mm 3 , saat ini belum tersedia di Indonesia. Untuk mengetahuinya, maka dilakukan penelitian ini. Desain penelitian kohort retrospektif, dilakukan pengamatan terhadap kematian pada populasi dinamis selama satu tahun (366 hari), dari Januari 2005 hingga Januari 2010. Subjek penelitian 158 pasien HIV/AIDS berusia > 15 tahun, naïve dan mendapat regimen ARV lini pertama di RSPI Prof.DR.Sulianti Saroso pada tahun 2005-2010. Prosedur analisis ketahanan hidup menggunakan metode Kaplan-Meier (product limit), analisis bivariat dengan Log rank test (Mantel cox) dan analisis multivariat dengan cox regression / cox proportional hazard model. Penelitian ini mendapatkan probabilitas ketahanan hidup keseluruhan satu tahun pasien HIV/AIDS dengan pengobatan regimen ARV lini pertama adalah 0,86 (CI 95% 0,79-0,91). Incident rate kematian (Hazard rate) kelompok jumlah sel CD4 3 adalah 8/10.000 orang hari (29/100 orang tahun), kelompok jumlah sel CD4 50-3 adalah 3/10.000 orang hari (11/100 orang tahun) dan kelompok jumlah sel CD4 > 200 sel/mm 3 adalah 2/10.000 orang hari (7/100 orang tahun). Hazard Ratio(HR)-adjusted kelompok jumlah sel CD4 <50 sel/mm 3 terhadap kelompok jumlah sel CD4 > 200 sel/mm 3 adalah 3,4 (p= 0,058 ; CI 95% : 0,96-12,16), HR-adjusted kelompok jumlah sel CD4 50-3 terhadap kelompok jumlah CD4 > 200 sel/mm 3 adalah 1,7 (p= 0,48 ; CI 95% : 0,4-7.04). HR-adjusted pasien dengan TB 3,57 kali terhadap pasien tanpa TB (p=0,015 ; CI 95% : 1,27-9,99). Jumlah sel CD4 sebelum pengobatan ARV tidak mempunyai pengaruh secara statistik terhadap ketahanan hidup satu tahun pasien HIV/AIDS yang mendapat regimen ARV lini pertama. Namun penelitian mendapatkan penyakit Tuberkulosis (TB) mempunyai pengaruh secara statistik terhadap ketahanan hidup satu tahun pasien HIV/AIDS yang mendapat regimen ARV lini pertama. Kata kunci: HIV/AIDS, jumlah sel CD4, pengobatan ARV, ketahanan hidup satu tahun.
HIV/AIDS disease is one of public health concerns in Indonesia. The growing issues related to high morbidity and mortality rate. This is due to such as lately initiated of Antiretroviral (ARV) therapy. In Indonesia ARV therapy is begun when the CD4 cell counts dropped below 200 cell/mm 3 or if clinical stadium fall into 3 rd th or 4 . Nowadays in Indonesia, Information about the influenced of baseline CD4 cell count to one year survival among patient HIV/AIDS with first line ARV regimen therapy, base on strata 3 , 50- 3 and > 200 cell/mm 3 was not available, therefore this research will be conducted. Study design was retrospective cohort, with one year (366 days) duration of observation to death, in dynamic population from January 2005 to January 2010. The subjects of study were 158 HIV/AIDS patients, with inclusion criteria: > 15 years old, naïve, and were treated by first line ARV regimen at RSPI Prof.DR. Sulianti Saroso in year 2005-2010. The procedures of survival analysis used Kaplan-Meier method (product limit), and Log rank test (Mantel cox) for bivariate analysis and cox regression / cox proportional hazard model for multivariat analysis. The overall of one year survival probability in HIV/AIDS patients with first line ARV regimen therapy was 0,86 (CI 95% 0,79-0,91). Incident rate of death (Hazard rate) in CD4 3 group was 8/10.000 persons days (29/100 persons years), in CD4 50-3 group was 3/10.000 persons days (11/100 persons years) and in CD4 > 200 cell/mm 3 group was 2/10.000 persons days (7/100 persons years). The Hazard Ratio(HR)-adjusted CD4 <50 cell/mm 3 patients compared to CD4 > 200 cell/mm 3 patients was 3,4 (p= 0,058 ; CI 95% : 0,96-12,16), the HR-adjusted CD4 50-3 patients compared to CD4 > 200 cell/mm 3 patients was 1,7 (p= 0,479 ; CI 95% : 0,4-7.04). HR- adjusted tuberculosis patients was 3,57 time more risk to death than patients without tuberculosis (p=0,015 ; CI 95% : 1,27-9,99). This study found that the baseline CD4 cell counts have not significant statistical associated to one year survival of HIV/AIDS patients with first line ARV regimen therapy, after has controlled to other independent variables. But this study found that tuberculosis has significant statistical association to one year survival of HIV/AIDS patients who received first line ARV regimen therapy. Keywords: HIV/AIDS, CD4 cell counts, treatment ARV, one year survival.
This study was aim to assess the effect of time to Antiretroviral Treatment (ART) onCD4 response failure in TB-HIV coinfection patients. This study was conductedfrom May to June 2016 at Infectious Disease Hospital Sulianti Saroso. This studyused cohort restrospective design with one and half year time to follow up. Studypopulation were TB-HIV coinfected patients, noted as a naive ART patient inmedical records from january 2010-november 2014. A total 164 patients ≥ 15 yearsold, had Anti Tuberculosis Treatment (ATT) 2 weeks before ART and had minimum2 CD4 sell count laboratorium test results. The cumulative probability of CD4response failure among TB-HIV co-infected patients was 14,43%. Hazard rate ofCD4 response failure was 767 per 10.000 person year in early ART (2-8 weeks afterATT) versus 474 per 10.000 person year in delayed ART (8 weeks after ATT) arm(p=0,266). In multivariate analysis using time independent cox regression test, rateof CD4 responses failure was lower in patients with delayed ART until 8 weeks afterATT than early ART 2-8 weeks after ATT. (Adjusted HR=0,502 ; 0,196-1,287 ; Pvalue=0,151) controlled by types of ARV regiments and classification of TB cure.Keywords: TB-HIV Co-infection, Antiretroviral treatment, CD4 response failure
Laporan Kemenkes RI mengenai angka kejadian HIV & AIDS di Indonesia sampai September menyatakan 92.251 kasus HIV dan 39.434 kasus AIDS. ODHA memerlukan ARV untuk menekan replikasi virus. Paduan pengobatan dimulai dari lini pertama yang terdiri atas 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI) dan 1 Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI). Nevirapin adalah ARV golongan NNRTI yang paling sering digunakan karena efektif dan efisien. Evaluasi pengobatan ARV dan data mengenai substitusi ARV masih kurang. Substitusi dapat menggambarkan isu penting berkaitan dengan keberhasilan program pengobatan HIV dan efek samping obat. Desain penelitian ini kasus kontrol dengan data berasal dari rekam medis. Kasus adalah mereka yang mengalami sustitusi nevirapin. Analisis univariat, bivariat dan multivariat logistik regresi dilakukan. Didapatkan faktor-faktor dominan yang berhubungan dengan substitusi nevirapin adalah tingkat pendidikan OR=3,31(CI95%=1,27-8,63) dan kondisi awal terapi yaitu stadium klinis OR=0,37 (CI95%=0,13-1,11), kadar SGOT OR=2,15 (CI95%=0,83-5,57), kadar SGPT dengan OR=1,41 (CI95%=0,61-3,26), dan CD4 dengan OR ==1,80 (CI95%=0,56-5,83). Edukasi kepada pasien dengan tingkat pendidikan rendah mengenai manfaat dan cara minum obat perlu lebih ditekankan dan monitoring keluhan efek samping secara teratur melalui pemeriksaan fisik dan pemeriksaan laborarium secara berkala kepada seluruh penderita HIV/AIDS yang mendapat ARV disertai CD4 dan enzim hati diawal terapi yang tinggi.
Indonesian Ministry of Health reported that there are 92.251 cases HIV and 39.434 cases AIDS until September 2012. Those people need ARV to suppress viral load dan enhaced their immunity. Based on guideline therapy, starting ARV should from first line which consisted of 2 NRTI (nucleoside reverse transcriptase inhibitor) dan 1 NNRTI (non-nucleoside reverse transcriptase inhibitor). Nevirapin is a NNRTI and more prescribe because its effectiveness and efficiency. In Indonesia, there are less data about antiretroviral evaluation, especially substitution. These data are important to identify some issues such as effectiveness antiretroviral therapy and toxicity. Toxicity that induced by antiretroviral effect nonadherence. This study is using case control design which source of data is medical records. Cases are those who experienced nevirapine substitution. Univariat, bivariat and multivariate logistic regression are using to analyze these data. Result shows that significant factors associated with nevirapine substitution are education level OR=3,31(CI95%=1,27-8,63), clinical staging OR=0,37 (CI95%=0,13-1,11), SGOT level at baseline OR=2,15 (CI95%=0,83-5,57), SGPT level at baseline OR=1,41 (CI95%=0,61-3,26), and CD4 at baseline OR ==1,80 (CI95%=0,56-5,83). This result recommend to educate those who are low education with comprehensive information about antiretroviral and monitoring regularly patients who have elevated level of liver enzime on baseline therapy.
IntroductionDramatically, Anti-Retroviral drug Therapy (ART) has reduced morbidity andmortality of People Living with HIV/AIDS (PLWHA). However, adherence toantiretroviral therapy has become a challenge because this therapy must beendured for a lifetime. Adherence to antiretroviral therapy is one of the factorsthat determine the success of treatment. Poor adherence to ARV therapy inIndonesia is arround 23-55%. The objective of this study was to determine theinfluence of medication non-adherence to the 3-years survival of patients withHIV/AIDS.MethodsThis study used a retrospective cohort design at RSPI Prof. Dr. Sulianti Saroso in2010-2012.ResultsThe cumulative survival probability of patients with HIV/AIDS at RSPI Prof. dr.Sulianti Saroso in the second year (24th month) was 95.6% and the third year (inthe 36th) was 91%. Multivariate analysis with Cox regression showed the factorsthat affected the 3-years survival of patients with HIV/AIDS are non-adherence toART, after controlled by initial CD4 count (aHR = 7.608; 95% CI: 1.664 to34.790), and non-compliance appointments, after controlled by opportunisticinfection, age and initial CD4 count (aHR = 2.456; 95% CI: 0.802 to 7.518).Among patient non-adherence to ART, non-compliance appointments affected the3-years survival of patients with HIV/AIDS, after controlled by initial CD4 count,sex, CPT, modes of HIV transmission, WHO clinical stage, opportunisticinfection, and age (aHR = 4.517 ; 95%CI : 0.729-27.987).DiscussionsNonadherence to ART may caused a failure of the suppression on HIV viral, thusincrease the possibility of HIV virus mutations that can lead to drug-resistant andultimately increase the risk of death. Poor adherence to appointments of takingdrugs in the first year also assumed the poor adherence of the next assignment totake drugs in the further, and show disobedience to ART, so it will increase therisk of death.RecomendationMonitoring coverage of medication adherence of patients with HIV/AIDS in aregular basis as the early warning on the risk of death among patients withHIV/AIDS.Keyword : non-adherence to ART, appointment keeping, retrospective cohort
Proportion of TB cases child reaches 10.45% (MOH, 2011). The percentage of visits to cases of TB in infants increased from 28.9% in 2009 to 34% in 2010 of all visits TB.Penelitian cases aims to determine the relationship of contact factors, the characteristics of toddlers and parents with the incidence of pulmonary tuberculosis in infants RSPI Prof Dr Sulianti Saroso in 2012.
